SOURCE: Ritter Pharmaceuticals
LOS ANGELES, CA--(Marketwired - Apr 23, 2013) - Andrew Ritter, president and CEO of Ritter Pharmaceuticals, Inc., was selected as a finalist for the third annual Healthcare Leadership Awards recently presented by The Los Angeles Business Journal. Andrew has been at the forefront of researching the physiological effects of lactose intolerance and has gathered the leading minds in the fields of gastroenterology and biological science to put the technology behind colonic adaptation to work against the condition. Andrew's leadership at Ritter Pharmaceuticals has positioned the company at the forefront of developing therapeutic treatments based on colonic adaptation which alters the microflora for digestive health benefits. Ritter's lead product is being developed to treat lactose intolerance.
The LA Business Journal honored their award recipients and finalists at a banquet on Thursday, April 18 and featured them in a special supplement to the publication, released on April 22. Andrew was recognized in the Research Executive category for his commitment to advancing the standard of lactose intolerant patient care by working to provide what may be the first medical treatment option for the more than 40 million Americans who suffer with mild to severe lactose intolerance.
"I am honored that the Los Angeles Business Journal's Awards committee has named me among the healthcare leaders in Los Angeles," said Andrew Ritter. "And, I applaud the Journal for acknowledging the important role that medical research has on our local economy and citizens," he added.
Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. Ritter is rapidly establishing itself as the world's leader in lactose intolerance research and development. Ritter's RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance.